Group 1 - The Global X China Core Technology ETF has officially launched on the Hong Kong Stock Exchange, providing investors with a tool to diversify risks in technology stock investments, focusing on seven high-growth technology sectors and 30 leading Chinese technology companies [1] - The ETF tracks the Future Asset China Technology 30 Index, which includes the top 30 companies in China with potential global competitiveness, with an average market capitalization of $65 billion [1] - The top five sectors represented in the ETF are biotechnology (22%), semiconductors (17%), consumer electronics (17%), electric vehicles (15%), and batteries (9%) [1] Group 2 - China's manufacturing sector has rapidly expanded, now accounting for 30% of global manufacturing, ranking first in the world, with high-tech manufacturing growth outpacing traditional manufacturing [2] - In 2024, China's total R&D expenditure reached 3.6 trillion RMB, a year-on-year increase of 8.3%, maintaining its position as the second-largest globally [2] - Key industries such as semiconductors, renewable energy, and artificial intelligence are national strategic priorities, with domestic companies achieving technological independence and gaining a foothold in global markets [2] Group 3 - The rise of China's technology industry is expected to continue, with upgrades in high-end manufacturing, increased R&D investment, and deeper globalization [3] - The core technology sectors defined by the ETF are crucial for China's self-reliance in high-end technology, including biotechnology, semiconductors, electric vehicles, batteries, medical technology, robotics, consumer electronics, solar energy, and software [3] - The investment strategy of the Global X China Core Technology ETF focuses on 30 leading domestic companies, characterized by broad growth prospects, high R&D spending ratios, and attractive valuation advantages [3]

Group 1 - The Global X China Core Technology ETF (03448) has officially launched on the Hong Kong Stock Exchange, providing investors with a tool to diversify risks in technology stock investments, focusing on seven high-growth technology sectors and 30 leading Chinese technology companies [1] - The ETF tracks the Future Asset China Technology 30 Index, which includes the top 30 companies in China with potential global competitiveness, with an average market capitalization of $65 billion [1] - The top five sectors represented in the ETF are biotechnology (22%), semiconductors (17%), consumer electronics (17%), electric vehicles (15%), and batteries (9%) [1] Group 2 - Over the past few decades, China's manufacturing scale has rapidly expanded, now accounting for 30% of global manufacturing, ranking first in the world [2] - High-tech manufacturing has outpaced traditional manufacturing, indicating China's advancement in the global value chain [2] - In 2024, China's total R&D expenditure reached 3.6 trillion RMB, a year-on-year increase of 8.3%, maintaining its position as the second-largest globally [2] Group 3 - The rise of China's technology industry is expected to continue, with upgrades in high-end manufacturing, increased R&D investment, and deeper globalization [3] - The core technology sectors defined by the ETF are crucial for China's self-reliance in high-end technology and include biotechnology, semiconductors, electric vehicles, batteries, medical technology, robotics, consumer electronics, solar energy, and software [3] - The leading Chinese technology companies are anticipated to significantly increase their domestic market share while becoming global leaders [3]

Group 1 - The core viewpoint is that China's high-end technology development presents investment opportunities, particularly in Chinese companies that can profit in overseas markets [1] - The structural rise of China's high-end technology and manufacturing sectors is supported by talent reserves, a complete industrial chain, and scale advantages, with private enterprises playing an increasingly important role [1] - The profitability of leading Chinese technology companies has improved over the past two quarters, and the MSCI China Index shows a forward P/E ratio of 11 times, indicating valuation advantages compared to other global markets [1] Group 2 - As of July 8, the Hang Seng AH Premium Index stands at 130.01, having declined nearly 10% this year, with an increasing number of companies trading at a discount in A-shares relative to H-shares [2] - The development of China's innovative pharmaceutical sector is still in its early stages, with external licensing models opening up future profit margins for these companies [2] - The total amount of external licensing transactions for Chinese innovative pharmaceutical companies reached $45.5 billion from January to May 2025, surpassing the total for the first half of 2024 [2] Group 3 - Future Asset Global Investment (Hong Kong) announced the launch of the Global X China Core Technology ETF on July 9, which will invest in 30 leading Chinese technology companies focusing on digital transformation, future mobility, and advanced solutions [2] - The ETF aims to help investors capture investment opportunities in the Chinese technology sector while reducing portfolio volatility through diversified industry distribution [3]